EU and US could reach trade deal this weekend - Reuters
Investing.com -- IQVIA Holdings Inc (NYSE:IQV) shares surged 7.9% after the clinical research services provider reported second-quarter earnings and revenue that exceeded analyst expectations, while also raising its full-year guidance.
The company posted adjusted earnings of $2.81 per share for the second quarter, beating analyst estimates of $2.77. Revenue came in at $4.02 billion, above the consensus forecast of $3.96 billion and representing a 5.3% increase YoY.
"IQVIA delivered strong financial results, with revenue above target and profit towards the high-end of expectations," said Ari Bousbib, chairman and CEO of IQVIA. "These results underscore the resilience of our global diversified portfolio and the team’s ability to execute consistently against our strategic and financial objectives."
The company’s Technology & Analytics Solutions segment was particularly strong, with revenue increasing 8.9% to $1.63 billion. Research & Development Solutions revenue grew 2.5% to $2.2 billion, while Contract Sales & Medical (TASE:BLWV) Solutions revenue rose 9.3% to $188 million.
IQVIA’s contracted backlog stood at $32.1 billion as of June 30, growing 5.1% YoY. The company reported a book-to-bill ratio of 1.12x for the quarter, with net new bookings of $2.5 billion.
For fiscal year 2025, IQVIA raised its guidance, now expecting revenue between $16.1 billion and $16.3 billion, compared to the analyst consensus of $16.07 billion. The company forecasts adjusted earnings per share of $11.75 to $12.05, versus analyst expectations of $11.83.
During the second quarter, IQVIA repurchased $607 million of its common stock, bringing first-half share repurchases to $1.03 billion. The company had $1.98 billion of share repurchase authorization remaining as of June 30.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.